{"url_path":"/sec/xfor/8-k/2026-05-13/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1501697/0001501697-26-000051-index.html","accession_number":"0001501697-26-000051","cik":"0001501697","ticker":"XFOR","issuer_name":"X4 Pharmaceuticals, Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501697/0001501697-26-000051-index.html","primary_entity_key":"0001501697","primary_entity_name":"X4 Pharmaceuticals, Inc"},"word_count":468,"has_tables":true,"body_markdown":"xfor-20260511\n0001501697TRUE00015016972026-05-112026-05-11\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 8-K/A\n\n(Amendment No. 1)\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d)\n\nof the Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported): May 11, 2026\n\nX4 PHARMACEUTICALS, INC.\n\n(Exact name of registrant as specified in its charter)\n\n         Delaware001-3829527-3181608\n\n        (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)\n\n61 North Beacon Street,4th Floor\n\nBoston,Massachusetts02134\n\n(Address of principal executive offices)(Zip Code)\n\n(857) 529-8300\n\n(Registrant’s telephone number, including area code)\n\nNot applicable\n\n(Former name or former address, if changed since last report)\n\n_______________________________________________________________________________________________________\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nCommon Stock, par value $0.001 per shareXFORThe Nasdaq Stock Market LLC\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐\n\nEXPLANATORY NOTE\n\nOn May 12, 2026, X4 Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) to report, among other things, the election of the three Class III director nominees to serve until the Company’s 2029 Annual Meeting of Stockholders. The Original 8-K inadvertently listed Michael S. Wyzga as a Class III director nominee in place of Murray W. Stewart, M.D.\n\nAccordingly, the Company is filing this Current Report on Form 8-K/A (this “Amended 8-K”) to amend the Original 8-K solely to correct this typographical error. This Amended 8-K does not otherwise modify or update the disclosures set forth in the Original 8-K.\n\n___________________________________________________________________________________________________\n\nOn May 11, 2026, the Company held its annual meeting of stockholders (the “Annual Meeting”) at 12:00 p.m. Eastern Time for which a quorum was present. As of the close of business on March 13, 2026, the record date for the Annual Meeting, there were 90,919,696 shares of common stock, par value $0.001 per share, outstanding and entitled to vote."}